Citations

Mayo Clinic

Showing 10 of 108599 citations.

Lymphoma classification update: B-cell non-Hodgkin lymphomas
Jiang, Manli, Feldman, Andrew L. , Bennani, N. Nora , Feldman, Andrew L

Expert Review of Hematology | April 11, 2017 | Volume: 10 | Issue: 5 | Pages: 405-415

10.1080/17474086.2017.1318053 | PMID 28395545 Get It

Percutaneous Pericardial Resection
Borlaug, Barry A. , Carter, Rickey E. , Melenovský, Vojtěch , Gaba, Prakriti , Killu, Ammar M. , Naksuk, Niyada , Lerman, Lilach O. , Asirvatham, Samuel J. , Killu, Ammar, Lerman, Lilach, DeSimone, Christopher V. , Asirvatham, Samuel J , Borlaug, Barry A , Carter, Rickey E , Melenovský, Vojtěch

Circulation: Heart Failure | April 11, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.116.003612 | PMID 28396500 Get It

Background— People with heart failure and preserved ejection fraction develop increases in left ventricular (LV) end-diastolic pressures during exercise that contribute to dyspnea. In normal open-chest animal preparations, the pericardium restrains LV filling when central blood volume increases. We hypothesized that resection of the pericardium using a minimally invasive epicardial approach would mitigate the increase in LV end-diastolic pressure that develops during volume loading in normal and diseased hearts with the chest intact. Methods and Results— Invasive hemodynamic assessment was performed at baseline and after saline load before and after pericardial resection in normal canines with open (n=3) and closed chest (n=5) and in a pig model with features of human heart failure and preserved ejection fraction with sternum intact (n=4). In closed-chest animals, pericardiotomy was performed using a novel subxiphoid procedure. In both experimental preparations of normal dogs, pericardiotomy blunted the increase in LV end-diastolic pressure with saline infusion, while enhancing the saline-mediated increase in LV end-diastolic volume. With chest intact in the pig model, percutaneous pericardial resection again blunted the increase in LV end-diastolic pressure secondary to volume expansion (+4±3 versus +13±5 mm Hg; P =0.014), while enhancing the saline-mediated increase in LV end-diastolic volume (+17±1 versus +10±2 mL; P =0.016). Conclusions— This proof of concept study demonstrates that pericardial resection through a minimally invasive percutaneous approach mitigates the elevation in LV filling pressures with volume loading in both normal animals and a pig model with diastolic dysfunction. Further study is warranted to determine whether this method is safe and produces similar acute and chronic hemodynamic benefits in people with heart failure and preserved ejection fraction.
A comparison of the diagnostic accuracy of magnetic resonance imaging to axillary ultrasound in the detection of axillary nodal metastases in newly diagnosed breast cancer
Assing, Matthew A., Patel, Bhavika , Karamsadkar, Neel, Weinfurtner, Jared, Kiluk, John V. , Drukteinis, Jennifer S. , Usmani, Omar S. , Patel, Bhavika K

The Breast Journal | April 10, 2017 | Volume: 23 | Issue: 6 | Pages: 647-655

10.1111/tbj.12812 | PMID 28397344 Get It

Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis
Blair, Janis E. , Wang, Sharon, Bercovitch, Robert, Bolaris, Michael , Akker, Dane Van Den, Heidari, Arash , Catanzaro, Antonino , Chin‐Hong, Peter , Spellberg, Brad , Johnson, Royce H. , Thompson, George R , López, Rodrigo , Cadena, José

Clinical Infectious Diseases | April 10, 2017 | Volume: 65 | Issue: 2 | Pages: 338-341

10.1093/cid/cix318 | PMID 28419259 Get It

Neovascularization Failure of an Interposed Free Intestinal Colon Flap 10 Years after Esophageal Reconstruction
Manrique, Oscar J. , Ciudad, Pedro , Chen, Shih‐Heng , Chen, Hung‐Chi

Journal of Reconstructive Microsurgery Open | April 10, 2017 | Volume: 02 | Issue: 01 | Pages: e35-e36

10.1055/s-0037-1601850 Get It

Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention
Weinberg, David S. , Lin, Jieru E. , Foster, Nathan R. , Della’Zanna, Gary , Seisler, Drew K., Katz, Leo C., Waldman, Scott A. , Seisler, Drew, Limburg, Paul J. , Umar, Asad , Kraft, Walter K. , Kastenberg, David , Waldman, Scott A

Cancer Prevention Research | April 10, 2017 | Volume: 10 | Issue: 6 | Pages: 345-354

10.1158/1940-6207.capr-16-0286 | PMID 28396341 Get It

Abstract Guanylate cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Linaclotide is an FDA-approved oral GUCY2C agonist formulated for gastric release, inducing fluid secretion into the small bowel to treat chronic idiopathic constipation. The ability of oral linaclotide to induce a pharmacodynamic response in epithelial cells of the colorectum in humans remains undefined. Here, we demonstrate that administration of 0.87 mg of oral linaclotide daily for 7 days to healthy volunteers, after oral colon preparation with polyethylene glycol solution (MoviPrep), activates GUCY2C, resulting in accumulation of its product cyclic (c)GMP in epithelial cells of the cecum, transverse colon, and distal rectum. GUCY2C activation by oral linaclotide was associated with homeostatic signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of proliferation quantified by reduced Ki67-positive epithelial cells. In the absence of the complete oral colonoscopy preparation, linaclotide did not alter cGMP production in epithelial cells of the colorectum, demonstrating that there was an effect related to the laxative preparation. These data show that the current FDA-approved formulation of oral linaclotide developed for small-bowel delivery to treat chronic idiopathic constipation is inadequate for reliably regulating GUCY2C in the colorectum to prevent tumorigenesis. The study results highlight the importance of developing a novel GUCY2C agonist formulated for release and activity targeted to the large intestine for colorectal cancer prevention. Cancer Prev Res; 10(6); 345–54. ©2017 AACR.
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Eroglu, Zeynep , Özgün, Alpaslan, Leger, Paul, Ye, Fei , Luke, Jason J. , Haq, Rizwan , Ott, Patrick A. , Hodi, F. Stephen , Sosman, Jeffrey A. , Johnson, Douglas B. , Buchbinder, Elizabeth I. , Wang, Daniel Y. , Zhao, Shilin , Joseph, Richard W. , Luke, Jason J

Cancer Immunology Research | April 10, 2017 | Volume: 5 | Issue: 5 | Pages: 357-362

10.1158/2326-6066.cir-16-0287 | PMID 28396509 Get It

Abstract Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti–PD-1 from three academic centers and identified 36 patients with acquired resistance, defined as disease progression following objective response. The incidence, timing, disease sites, post-progression survival (PPS), and outcomes were evaluated descriptively. The acquired resistance cohort consisted of 67% with more than 1 feature of poor prognosis (stage M1c, elevated LDH, or brain metastasis), and 67% had previously received ipilimumab. Partial and complete responses were achieved in 89% (n = 32) and 11% (n = 4) of patients, respectively, and median time to resistance (progression-free survival; PFS) was 11.1 months (range 4.3–32.8 months). Most progression was isolated (78% of patients, n = 28) and occurred while receiving therapy (78%, n = 28). The median PPS was 12.8 months (range 0.1–51.8 months), and the median overall survival was 33.7 months. Among isolated progressors, 15 received localized therapy (12 with surgery, 3 with radiation). Patients with isolated versus systemic progression exhibited a trend for improved PPS (P = 0.081), and patients with an initial PFS ≥ 15 months showed significant PPS improvement (P = 0.036). Two patients experienced subsequent responses to anti–PD-1 resumption. In conclusion, acquired resistance to anti–PD-1 was frequently associated with excellent clinical outcomes and often presented as isolated progression amenable to localized therapy (surgery or radiation) or systemic progression sensitive to therapy resumption. Cancer Immunol Res; 5(5); 357–62. ©2017 AACR.
Medical Education at Mayo Clinic (Mayo Medical School)
Daube, Jasper R.

Journal of UOEH | April 10, 2017 | Volume: 13 | Issue: 3 | Pages: 207-215

10.7888/juoeh.13.207 | PMID 1925144 Get It

Neuroembryology of the Acupuncture Principal Meridians: Part 2. The Trunk
Dorsher, Peter T.

Medical Acupuncture | April 10, 2017 | Volume: 29 | Issue: 2 | Pages: 77-86

10.1089/acu.2016.1211 Get It

ThT 101: a primer on the use of thioflavin T to investigate amyloid formation
Malmos, Kirsten Gade , Blancas‐Mejía, Luis M. , Weber, Benedikt , Büchner, Johannes , Ramı́rez-Alvarado, Marina , Naiki, Hironobu , Otzen, Daniel E. , Otzen, Daniel , Ramirez-Alvarado, Marina

Amyloid | April 10, 2017 | Volume: 24 | Issue: 1 | Pages: 1-16

10.1080/13506129.2017.1304905 | PMID 28393556 Get It